Sudocetaxel Zendusortide (TH1902) triggers the cGAS/STING pathway and potentiates anti-PD-L1 immune-mediated tumor...

The development of effective treatments for aggressive malignancies like triple-negative breast cancer remains a significant challenge in modern oncology. It was already known that sortilin acts as a specialized scavenger receptor that is frequently overexpressed on the surface of various invasive tumor cells. Traditional taxane-based therapies often encounter limitations due to poor intratumoral penetration or severe systemic toxicities that restrict their therapeutic window. Scientists have long sought methods to deliver cytotoxic payloads more precisely while simultaneously stimulating the host's innate immune response within the tumor microenvironment. The complex interplay between direct cell death and the recruitment of immune effectors is a critical area of ongoing investigation. This gap motivated the exploration of how sortilin-targeted peptide-drug conjugates can modulate the cancer-immunity cycle to achieve sustained regression.

Researchers evaluated the antitumor efficacy and immune-modulatory properties of Sudocetaxel Zendusortide (TH1902) across multiple preclinical cancer models. The investigation sought to determine if sortilin-mediated internalization of this conjugate could trigger complete tumor regression in immunocompromised triple-negative breast cancer xenografts. Scientists aimed to compare the growth inhibitory effects of this novel agent against standard docetaxel treatments in syngeneic melanoma environments. The team analyzed the specific recruitment patterns of Cluster of Differentiation 45 (CD45) positive leukocytes following administration of the compound. Another primary objective involved assessing the synergistic potential of combining this sortilin-targeted therapy with Programmed Death-Ligand 1 (PD-L1) checkpoint inhibitors. The study also examined the intracellular signaling pathways, specifically focusing on the induction of senescence and apoptotic markers in vitro.

The study utilized MDA-MB-231 xenograft models to observe long-term regression patterns following the final administration of the therapeutic agent. B16-F10 melanoma syngeneic murine models provided essential data regarding the interaction between the drug and a functional immune system. Immunohistochemistry (IHC) analysis quantified the presence of Stimulator of Interferon Genes (STING) within the treated tumor tissues to assess pathway activation. Flow cytometry identified the infiltration of specific immune subsets, including Tumor-Infiltrating Lymphocytes (TILs) and Tumor-Associated Macrophages (TAMs). In vitro assays measured the expression of Major Histocompatibility Complex Class I (MHC-I) and various downstream effectors of the cGAS/STING signaling cascade. Researchers also monitored animal survival rates and median life expectancy across different combination treatment cohorts. Statistical frameworks compared the inhibitory performance of the peptide-drug conjugate against conventional docetaxel monotherapy.

TH1902 induced complete tumor regression for over 40 days in the MDA-MB-231 xenograft model after the cessation of treatment. Weekly administration in B16-F10 melanoma models demonstrated significantly higher growth inhibition compared to conventional docetaxel applications. Treated tumors exhibited a net increase in CD45 leukocyte infiltration, with a specific enrichment of TILs and TAMs within the microenvironment. Elevated levels of perforin, granzyme B, and caspase-3 indicated enhanced cytotoxic T cell and Natural Killer (NK) cell activity in response to the conjugate. Combination therapy with anti-PD-L1 antibodies resulted in improved median animal survival and a marked suppression of tumor expansion. In vitro experiments confirmed that the agent triggers apoptosis and senescence while upregulating MHC-I and PD-L1 expression in B16-F10 cells. These observations suggest that the compound functions as a potent activator of the Cyclic GMP-AMP Synthase (cGAS) and STING pathway.

These findings suggest that Sudocetaxel Zendusortide functions through the dual mechanism of direct cytotoxicity and modulation of the immune tumor microenvironment. Activation of the cGAS/STING pathway represents a novel and significant therapeutic mechanism for this sortilin-targeted peptide-drug conjugate. The observed induction of MHC-I and PD-L1 expression provides a strong mechanistic rationale for future clinical trials involving checkpoint inhibitors. Enhanced leukocyte recruitment suggests that this treatment can effectively shift the tumor phenotype from an immune-excluded to an immune-active state. Future research should focus on the clinical translation of these synergistic combinations in patients with sortilin-positive cancers. The study highlights the potential for PDCs to improve animal survival and clinical outcomes when paired with established immunotherapies. These results establish a foundation for utilizing targeted delivery systems to overcome traditional resistance in aggressive breast and skin cancers.